[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![_Investor_Feed_ Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1825090112713285632.png) Investor Feed [@_Investor_Feed_](/creator/twitter/_Investor_Feed_) on x 6181 followers
Created: 2025-07-02 11:28:45 UTC

Aurobindo Pharma’s CuraTeQ Scores Another EU Approval with Dazublys™ 🎯 | MCap XXXXXXXXX Cr

- CuraTeQ Biologics (Aurobindo Pharma subsidiary) gains European Commission approval for trastuzumab biosimilar Dazublys™.
- EMA’s CHMP gave a positive opinion for Dazublys™ in April 2025.
- Dazublys™ is CuraTeQ’s third EMA-approved biosimilar, following Dyrupeg™ (April 2025) and Zefylti™ (February 2025).
- Fourth biosimilar approval in the EU for CuraTeQ, including Bevqolva™ (UK MHRA-approved in December 2024).

Disc: Information provided in this tweet can be inaccurate, verify through the source before making any investment decision.

![](https://pbs.twimg.com/media/Gu2WFAtXEAEcaAg.jpg)

XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1940372064604459401/c:line.svg)

**Related Topics**
[mcap](/topic/mcap)
[aurobindo pharma](/topic/aurobindo-pharma)
[$auropharmans](/topic/$auropharmans)
[investment](/topic/investment)

[Post Link](https://x.com/_Investor_Feed_/status/1940372064604459401)